RT Journal Article
SR Electronic
T1 Elevated Angiopoietin-2 inhibits thrombomodulin-mediated anticoagulation in critically ill COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.13.21249429
DO 10.1101/2021.01.13.21249429
A1 Michael Hultström
A1 Karin Fromell
A1 Anders Larsson
A1 Susan E Quaggin
A1 Christer Betsholtz
A1 Robert Frithiof
A1 Miklos Lipcsey
A1 Marie Jeansson
YR 2021
UL http://medrxiv.org/content/early/2021/01/15/2021.01.13.21249429.abstract
AB Several studies suggest that hypercoagulation and endothelial dysfunction play central roles in severe forms of COVID-19. Here, we hypothesized that the high levels of the inflammatory cytokine Angiopoietin-2 (ANGPT2) reported in hospitalized COVID-19 patients might promote hypercoagulation through ANGPT2 binding to thrombomodulin with resulting inhibition of thrombin/thrombomodulin-mediated physiological anticoagulation. We therefore investigated plasma samples taken at two timepoints from 20 critically ill COVID-19 patients in intensive care regarding ANGPT2 levels and coagulation markers in comparison with 20 healthy blood donors. We found that ANGPT2 levels were increased in the COVID-19 patients in correlation with disease severity, hypercoagulation, and mortality. To test causality, we administered ANGPT2 to wildtype mice and found that it shortened bleeding time in a tail injury model. In further support of a role for ANGPT2 in physiological coagulation, bleeding time was increased in endothelial-specific Angpt2 knockout mice. Using in vitro assays, we found that ANGPT2 inhibited thrombomodulin-mediated anticoagulation and protein C activation in human donor plasma. Our data reveal a novel mechanism for ANGPT2 in hypercoagulation and suggest that Angiopoietin-2 inhibition may be tested in the treatment of hypercoagulation in severe COVID-19, as well as in certain other conditions, including sepsis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the SciLifeLab/KAW national COVID-19 research program project grant to MH (KAW 2020.0182), the Swedish Research Council grant to RF (2014-02569 and 2014-07606), and Swedish Research Council grant (2012-865), Ake Wiberg Foundation, Magnus Bergwall Foundation, IGP Young Investigator Award to MJ. The laboratory of C.B. is funded by grants from the Swedish Research Council, the Swedish Cancer Society, and the Knut and Alice Wallenberg Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swedish Ethical Review Authority at the Ministry of Education and Research for patient samples (approved permit 2020-01623) and blood donor samples (approved permit 01/367), in accordance with the Swedish Ethical Review Act (SFS 2003:460). Informed consent was obtained from the patient, or next of kin if the patient was unable to give consent. The Declaration of Helsinki and its subsequent revisions were followed. STROBE guidelines were followed for reporting. All animal experiments were approved by the Uppsala Committee of Ethics of Animal Experiments (approved permit 5.8.18-04862-2020), in accordance with the Swedish Animal Protection Act (SFS 1988:534), and were conducted according to guidelines established by the Swedish Board of Agriculture. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are presented within the manuscript